Autoantibody Diagnostic Kit Segmentation for False Positive Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for identifying cancer or autoimmune conditions are hindered by false positive indicators due to the presence of common autoantibodies in healthy individuals, which can confound disease-linked autoantibody identification and diagnosis.
Innovation Solution
A method and kit for detecting specific autoantibodies against listed autoantigens in biological samples to identify false positive indicators, utilizing a comprehensive list of common autoantibodies to increase diagnostic accuracy by distinguishing between true and false positive results.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If autoantibodies are used as diagnostic markers for cancer or autoimmune conditions, then diagnostic sensitivity is improved, but false positive rate increases due to presence of common autoantibodies in healthy individuals
Solution Approach 1:
The patent segments the diagnostic process into two distinct stages: (1) initial screening using a panel of autoantibody markers to detect potential disease presence, and (2) verification stage using a separate panel of control autoantigens to distinguish true positives from false positives. This segmentation allows the system to maintain high sensitivity while reducing false positive rates by systematically eliminating common autoantibody interference.
Solution Approach 2:
The patent introduces control autoantigens as intermediary elements that mediate between the diagnostic challenge (distinguishing disease-specific autoantibodies from common autoantibodies) and the solution. These control autoantigens serve as reference markers that do not cross-react with disease-specific autoantibodies, thereby providing a baseline to identify and exclude false positive results while preserving true positive detections.
2Adaptability or versatility
If a comprehensive panel of autoantibody markers is used to screen for diseases, then detection coverage is improved, but diagnostic complexity increases
Solution Approach 1:
The comprehensive diagnostic panel is segmented into two functional subsets: a disease detection panel targeting disease-specific autoantigens and a verification panel targeting control autoantigens. This segmentation organizes the complexity into manageable, purpose-driven modules that can be independently optimized and interpreted, reducing the cognitive and operational burden despite the comprehensive nature of the screening.
Solution Approach 2:
The control autoantigen panel serves multiple functions simultaneously: it verifies true positives, excludes false positives, provides a baseline for comparison, and validates assay performance. This multi-functionality reduces overall diagnostic complexity by consolidating multiple verification steps into a single universal control mechanism that handles various diagnostic challenges.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enhances the accuracy of cancer or autoimmune condition screening by identifying false positives, thereby improving diagnostic reliability and reducing misclassification.
Implementation Method 1
detecting the presence of one or more autoantibodies against at least one autoantigen listed in Table 1 in the biological sample
Data Source
AI summary
The present invention relates autoantibody biomarkers, kits, and methods for increasing the accuracy of a cancer or autoimmune screening of a subject suspected of having cancer or an autoimmune condition.